Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort NeuroScientific Corporation
微創腦科學有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2172)

VOLUNTARY ANNOUNCEMENT
APOLLO Dream® Rapamycin Target Eluting Stent System Granted FDA Breakthrough Device Designation

This announcement is made by MicroPort NeuroScientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that APOLLO Dream® Rapamycin Target Eluting Stent System ("**APOLLO Dream® Stent System**"), independently developed by the Group, has been granted the Breakthrough Device Designation ("**Breakthrough Device Designation**") by the U.S. Food and Drug Administration ("**FDA**") recently, being the world's first balloon-expandable, rapid exchange drug-eluting stent in the neuro-interventional field to receive this designation.

The APOLLO Dream® Stent System is specifically designed for patients with symptomatic intracranial arterial stenosis who are refractory to best medical therapy. The system integrates targeted drug-eluting technology with an optimized stent mechanical structure, providing stable vascular scaffolding and restoring cerebral blood flow, while targeted delivery of rapamycin to the vessel wall inhibits vascular smooth muscle cell proliferation, thereby reducing the risk of in-stent restenosis.

Compared with conventional drug-eluting stents, APOLLO Dream® Stent System enables more precise control of drug-release dosage, significantly reducing the total systemic drug load while maintaining therapeutic efficacy. Its drug coating utilizes biodegradable materials, which gradually degrade after drug release is completed, potentially lowering the long-term risk of thrombosis.

The Breakthrough Device Designation is intended to be granted to innovative medical technologies that are developed for life-threatening or irreversibly debilitating diseases and that demonstrate the potential to provide significant clinical advantages. APOLLO Dream® Stent System is the world's first balloon-expandable, rapid exchange drug-eluting stent in the neuro-interventional field to receive the designation. This recognition highlights:

- The technological innovation and potential clinical value of the APOLLO Dream® Stent System in the treatment of intracranial atherosclerotic disease (ICAD) have been recognized by an international authoritative regulatory body;

- It will help accelerate the clinical development and regulatory review process of the device;

- It is expected to fill the market gap of the treatment of intracranial atherosclerotic stenosis with drug stent overseas and to benefit patients worldwide; and

- It lays an important foundation for the Group to advance its globalization strategy and accelerate its entry into key international markets.

Looking ahead, the Group will continue to advance the global clinical studies and registration process of the APOLLO Dream® Stent System, further expand the Company's international influence in the neurovascular interventional innovative therapy, and provide more advanced treatment options for patients worldwide.

There can be no assurance that the APOLLO Dream® Stent System will be successfully commercialized. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, March 18, 2026

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.